Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study (Q40179597)

From Wikidata

Jump to navigation Jump to search

scientific article published on 30 May 2017

Language	Label	Description	Also known as
English	Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study	scientific article published on 30 May 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

electroporation

1 reference

based on heuristic

inferred from title

Marc G Besselink

14

object named as

Marc G Besselink

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Thomas van Gulik

6

object named as

Thomas M van Gulik

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Olivier R. C. Busch

13

object named as

Olivier R Busch

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Otto M van Delden

4

object named as

Otto M van Delden

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Krijn P van Lienden

12

object named as

Krijn P van Lienden

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

Jantien A Vogel

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Steffi J Rombouts

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Thijs de Rooij

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Marcel G Dijkgraaf

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Jeanin E van Hooft

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Hanneke W van Laarhoven

8

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Robert C Martin

9

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Annuska Schoorlemmer

10

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Johanna W Wilmink

11

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

publication date

30 May 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Annals of Surgical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

2734-2743

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Stochastic model for electric field-induced membrane pores. Electroporation

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Tissue ablation with irreversible electroporation.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Cancer cells ablation with irreversible electroporation

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

In vivo results of a new focal tissue ablation technique: irreversible electroporation

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Tumor ablation with irreversible electroporation

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Vascular smooth muscle cells ablation with endovascular nonthermal irreversible electroporation

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

The effect of irreversible electroporation on blood vessels

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Irreversible electroporation: a new ablation modality--clinical implications

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Irreversible electroporation of the liver and liver hilum in swine.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Assessment of chronological effects of irreversible electroporation on hilar bile ducts in a porcine model

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

The effects of irreversible electroporation (IRE) on nerves

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Acute and subacute effects of irreversible electroporation on nerves: experimental study in a pig model.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

The delayed effects of irreversible electroporation ablation on nerves

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Low vulnerability of the right phrenic nerve to electroporation ablation

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Irreversible electroporation of unresectable soft tissue tumors with vascular invasion: effective palliation

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

The Clavien-Dindo classification of surgical complications: five-year experience.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Redefining the R1 resection in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Redefining resection margin status in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Systematic review of outcomes after distal pancreatectomy with coeliac axis resection for locally advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-017-5900-9

21 January 2018

Identifiers

10.1245/S10434-017-5900-9

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40179597&oldid=2221728813"